The startup develops pharmaceutical drugs targeting chronic sinusitis by specifically addressing bacterial and fungal pathogens that contribute to otitis externa. Their treatments provide physicians with effective options to manage sinus and ear conditions, improving patient outcomes.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals suffer from sinusitis and otitis externa, with many chronic sinusitis patients requiring surgery, yet symptoms often persist post-surgery. Additionally, a significant percentage of otitis externa cases are fungal-based, and misdiagnosis can exacerbate these infections.
Solution
Oticara is a clinical-stage pharmaceutical company developing treatments for unresolved sinus and ear conditions. For sinusitis, they offer a novel treatment for eosinophilic chronic sinusitis patients with persistent symptoms after functional endoscopic sinus surgery (FESS); clinical studies have demonstrated statistically significant symptom improvement. For otitis externa, Oticara provides a patented, single-dose, in-office treatment targeting common bacterial and fungal pathogens, resolving infections regardless of the underlying cause. This approach addresses the issue of misdiagnosis and ineffective antibiotic use, which can increase fungal-based ear infections.
Target Audience
The primary target audience includes ENT physicians treating patients with sinusitis and otitis externa.
Features
- OTICARA SINUSITIS: Patent-pending treatment for eosinophilic chronic sinusitis post-FESS, with completed proof-of-concept clinical study.
- OTICARA OTIC: Patented, one-dose, in-office treatment for bacterial and fungal otitis externa, having completed an IRB-approved phase 2 proof-of-concept clinical study and middle ear toxicology.
- Treatments target both bacterial and fungal pathogens.
- Demonstrated significant reduction of symptoms in post-FESS sinusitis patients in clinical use.
- Addresses misdiagnosis of fungal-based infections and the use of ineffective antibiotic treatments.